Galapagos NV announced that its experimental drug for bowel disease did not meet a significant Phase II mark.
A French criminal investigation is underway following a failed drugs trial for Portuguese drug company Bial that resulted in one confirmed death and five serious hospitalizations.
An experimental drug has left one participant brain dead and five others in critical condition, the French health ministry stated.
People who are considered to be at-risk of heart attack and stroke should get blood pressure treatment even if their levels are normal, a new study is reporting.
A second participant involved in Zafgen's late phase trial for an obesity drug has died.
The latest results from a Phase III trial testing the effects of a drug for a hard-to-treat type of multiple sclerosis (MS) are not promising, a new study reported.
For the first time, a research has enabled detection of a genetic 'brittle bone' disease known as Osteogenesis Imperfecta (OI) by simply scanning a patient's limbs. Up until now, bone diseases have been diagnosed through X-rays, history of fractures and other clinical symptoms and, in the case of OI, genetic testing.
In a recent study, researchers used stem cells to treat Parkinson's disease in rats.
The World Health Organization announced that for the first half of next year, there should be around 200,000 doses of the Ebola vaccine available.
According to a clinical trial, a form of gene therapy might be an effective and safe treatment option for patients with severe combined immune deficiency (SCID).
According to researchers, a Pfizer drug was effective in shrinking the tumor size in patients with a rare form of lung cancer.
The NIH has distributed $10.2 million in additional funding for researchers to examine the role of gender in their trials.
The first two human trials for GlaxoSmithKline's experimental Ebola vaccine have started, according to health officials from the United States and the United Kingdom.
Two hospitals in the United States are set to begin trials to test Apple's HealthKit.
According to researchers from Stanford University School of Medicine, re-examining roughly one-third of the available randomized clinical trials resulted in very different results.